Laboratory Co. of America Holdings (NYSE:LH) Director Kerrii B. Anderson Sells 250 Shares

Laboratory Co. of America Holdings (NYSE:LH) Director Kerrii B. Anderson sold 250 shares of the business’s stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $204.13, for a total value of $51,032.50. Following the transaction, the director now directly owns 15,972 shares of the company’s stock, valued at approximately $3,260,364.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Laboratory Co. of America Trading Up 0.5 %

NYSE LH opened at $201.32 on Friday. The stock has a market cap of $16.97 billion, a P/E ratio of 40.51, a price-to-earnings-growth ratio of 1.51 and a beta of 1.02. Laboratory Co. of America Holdings has a fifty-two week low of $174.20 and a fifty-two week high of $234.09. The stock has a 50 day simple moving average of $210.12 and a two-hundred day simple moving average of $214.70. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.76 and a current ratio of 0.88.

Laboratory Co. of America (NYSE:LH) last announced its quarterly earnings results on Thursday, April 25th. The medical research company reported $3.68 EPS for the quarter, topping analysts’ consensus estimates of $3.48 by $0.20. The company had revenue of $3.18 billion during the quarter, compared to analyst estimates of $3.12 billion. Laboratory Co. of America had a return on equity of 14.68% and a net margin of 3.52%. The firm’s revenue was up 4.6% on a year-over-year basis. During the same quarter last year, the firm posted $3.82 earnings per share. On average, analysts forecast that Laboratory Co. of America Holdings will post 14.87 earnings per share for the current year.

Laboratory Co. of America Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, June 12th. Investors of record on Tuesday, May 28th will be paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 1.43%. The ex-dividend date is Tuesday, May 28th. Laboratory Co. of America’s payout ratio is currently 57.95%.

Institutional Trading of Laboratory Co. of America

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Provence Wealth Management Group bought a new position in shares of Laboratory Co. of America in the 3rd quarter worth approximately $29,000. Mendota Financial Group LLC bought a new position in Laboratory Co. of America in the fourth quarter worth $29,000. Tradewinds Capital Management LLC purchased a new position in Laboratory Co. of America during the third quarter valued at $34,000. Exchange Traded Concepts LLC purchased a new stake in shares of Laboratory Co. of America in the 3rd quarter worth about $37,000. Finally, McClarren Financial Advisors Inc. increased its stake in shares of Laboratory Co. of America by 313.2% in the 1st quarter. McClarren Financial Advisors Inc. now owns 219 shares of the medical research company’s stock worth $48,000 after acquiring an additional 166 shares in the last quarter. 95.94% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on LH shares. Robert W. Baird cut their price target on shares of Laboratory Co. of America from $255.00 to $244.00 and set an “outperform” rating for the company in a research note on Friday, April 26th. Barclays reduced their price objective on Laboratory Co. of America from $234.00 to $213.00 and set an “equal weight” rating on the stock in a research report on Friday, April 26th. TheStreet downgraded Laboratory Co. of America from a “b-” rating to a “c+” rating in a research report on Thursday, February 15th. Evercore ISI began coverage on shares of Laboratory Co. of America in a research note on Friday, February 9th. They set an “in-line” rating and a $240.00 price target on the stock. Finally, Leerink Partnrs reaffirmed an “outperform” rating on shares of Laboratory Co. of America in a research note on Monday, February 26th. Four research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat, Laboratory Co. of America has an average rating of “Moderate Buy” and an average price target of $243.14.

About Laboratory Co. of America

Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS).